TY - JOUR
T1 - Interrelationships between molecular subtype, anatomical location, and extent of resection in diffuse glioma
T2 - A systematic review and meta-analysis
AU - De Leeuw, Beverly I
AU - Van Baarsen, Kirsten M
AU - Snijders, Tom J
AU - Robe, Pierre A J T
N1 - Publisher Copyright:
© 2019 The Author(s) 2019. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Background: The introduction of the 2016 WHO Classification of Tumors of the Central Nervous System has resulted in tumor groupings with improved prognostic value for diffuse glioma patients. Molecular subtype, primarily based on IDH-mutational status and 1p/19q-status, is a strong predictor of survival. It is unclear to what extent this finding may be mediated by differences in anatomical location and surgical resectability among molecular subgroups. Our aim was to elucidate possible correlations between (1) molecular subtype and anatomical location and (2) molecular subtype and extent of resection.Methods: We performed a systematic review of literature searching for studies on molecular subtype in relation to anatomical location and extent of resection. Only original data concerning adult participants suffering from cerebral diffuse glioma were included. Studies adopting similar outcomes measures were included in our meta-analysis.Results: In the systematic analysis for research questions 1 and 2, totals of 20 and 9 studies were included, respectively. Study findings demonstrated that IDH-mutant tumors were significantly more frequently located in the frontal lobe and less often in the temporal lobe compared with IDH-wildtype gliomas. Within the IDH-mutant group, 1p/19q-codeleted tumors were associated with more frequent frontal and less frequent temporal localization compared with 1p/19q-intact tumors. In IDH-mutant gliomas, greater extent of resection was achieved than in IDH-wildtype tumors.Conclusions: Genetic profile of diffuse cerebral glioma influences their anatomical location and seems to affect tumor resectability.
AB - Background: The introduction of the 2016 WHO Classification of Tumors of the Central Nervous System has resulted in tumor groupings with improved prognostic value for diffuse glioma patients. Molecular subtype, primarily based on IDH-mutational status and 1p/19q-status, is a strong predictor of survival. It is unclear to what extent this finding may be mediated by differences in anatomical location and surgical resectability among molecular subgroups. Our aim was to elucidate possible correlations between (1) molecular subtype and anatomical location and (2) molecular subtype and extent of resection.Methods: We performed a systematic review of literature searching for studies on molecular subtype in relation to anatomical location and extent of resection. Only original data concerning adult participants suffering from cerebral diffuse glioma were included. Studies adopting similar outcomes measures were included in our meta-analysis.Results: In the systematic analysis for research questions 1 and 2, totals of 20 and 9 studies were included, respectively. Study findings demonstrated that IDH-mutant tumors were significantly more frequently located in the frontal lobe and less often in the temporal lobe compared with IDH-wildtype gliomas. Within the IDH-mutant group, 1p/19q-codeleted tumors were associated with more frequent frontal and less frequent temporal localization compared with 1p/19q-intact tumors. In IDH-mutant gliomas, greater extent of resection was achieved than in IDH-wildtype tumors.Conclusions: Genetic profile of diffuse cerebral glioma influences their anatomical location and seems to affect tumor resectability.
KW - WHO 2016 Classification
KW - extent of resection
KW - glioma
KW - location
KW - molecular markers
UR - http://www.scopus.com/inward/record.url?scp=85117952383&partnerID=8YFLogxK
U2 - 10.1093/noajnl/vdz032
DO - 10.1093/noajnl/vdz032
M3 - Review article
C2 - 32642663
SN - 2632-2498
VL - 1
SP - 1
EP - 12
JO - Neuro-oncology advances
JF - Neuro-oncology advances
IS - 1
M1 - vdz032
ER -